

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Application Number	10/657,363
Filing Date	September 8, 2003
First Named Inventor	Young et al.
Art Unit	1648
Examiner Name	Hill, Myron G.
Attorney Docket No.	10271-159-999

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	K31	WO 01/77137 (w/out Seq. List.)	10/18/2001	Human Genome Sciences		
	K32	WO 09/03019	12/31/08	MedImmune, Inc.		
	K33	WO 06/34292	03/30/06	MedImmune, Inc.		
	K34	WO 07/02543	01/04/07	MedImmune, Inc.		

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	L86	ADAMS et al., 1998, Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu", Br J Cancer; 77(9): 1405-12	
	L87	BENNETT et al., 2007, Immunopathogenesis of Respiratory Syncytial Virus Bronchiolitis, J Infect Dis; 195(10):1532-1540	
	L88	CARLSSON et al., 1992, Human peripheral blood lymphocytes transplanted into SCID mice constitute an in vivo culture system exhibiting several parameters found in a normal humoral immune response and are a source of immunocytes for the production of human monoclonal antibodies. J Immunol. 1992; 148(4):1065-71.	
	L89	CROWE et al., 1993, Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice, Proc Natl Acad Sci USA; 91:1386-1390	
	L90	DE VINCENZO et al., 2005, Factors Predicting Childhood Respiratory Syncytial Virus Severity - What They Indicate About Pathogenesis, Ped Inf Dis; 24:S177-S183	
	L91	IFVERSON and BORREBAECK, 1996, SCID-hu-PBL: a model for making human antibodies? Semin Immunol. 8(4):243-8.	

LAI-3016802v1

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Application Number	10/657,363
Filing Date	September 8, 2003
First Named Inventor	Young et al.
Art Unit	1648
Examiner Name	Hill, Myron G.
Attorney Docket No.	10271-159-999

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	L92	HEMMING et al., 1988, Topically Administered Immunoglobulin Reduces Pulmonary Respiratory Syncytial Virus Shedding in Owl Monkeys, Antimicrob Agents Chemother; 32(8):1269-1270	
	L93	KRISHNAN et al., 2008, Therapeutic addition of motavizumab, a monoclonal antibody against respiratory syncytial virus (RSV), modulates epithelial cell responses to RSV infection., Annual Interscience Conf Antimicrobial Agents Chemotherapy/Annual Meet Infect Dis Soc Am; 48/46 October 28 Abstract V-4147	
	L94	KUDO et al., 1992, New strategies to establish human monoclonal antibodies; Tohoku J Exp Med. 168(2):323-327.	
	L95	KUDO et al., 1993, Production of a human monoclonal antibody to a synthetic peptide by active in vivo immunization using a SCID mouse grafted with human lymphocytes; Tohoku J Exp Med. 171: 327-338.	
	L96	LAGOS et al., 2005, Administration of the anti-RSV monoclonal antibody (Mab) Numax™, is associated with a reduction in upper airway (UA) RSV load, World Congress Pediatr Infect Disease; September 1-4	
	L97	MACCALLUM et al., 1996, Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol. 262(5):732-45.	
	L98	MCCALL et al., 1999, Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytotoxicity. Mol Immunol. 1999 May;36(7):433-45.	
	L99	PRINCE et al., 1987, Effectiveness of Topically Administered Neutralizing Antibodies in Experimental Immunotherapy of Respiratory Syncytial Virus Infection in Cotton Rats, J Virol; 61(6):1851-1854	
	L100	RICHTER et al., 2008, Respiratory syncytial virus (RSV) therapy utilizing intranasally delivered motavizumab, a monoclonal antibody against F protein, Annual Interscience Conf Antimicrobial Agents Chemotherapy/Annual Meet Infect Dis Soc Am; 48/46 October 28 Abstract V-4145	
	L101	SEEVER, 1994, Monoclonal antibodies in industry: More difficult than originally thought; Genetic Engineering News, Vol. 14, No. 14, p. 10 and 21.	
	L102	STOTT et al., 1984, The characterization and uses of monoclonal antibodies to respiratory syncytial virus. Dev Biol Stand. 57:237-44.	
	L103	WARE et al., 1985, Human, rat or mouse hybridomas secrete high levels of monoclonal antibodies following transplantation into mice with severe combined immunodeficiency disease (SCID). J Immunol Methods. 85(2):353-61.	
	L104	WATKINS et al., 1998, Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antibody libraries. Anal Biochem. 256(2):169-77.	
	L105	WU et al., 2008, Immunoprophylaxis of RSV Infection: Advancing from RSV-IGIV to Palivizumab and Motavizumab, Curr Topics Microbiol Immunol; 317:103-123	

LAJ-3016802v1

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.